Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-s...

by Einstein, Mark H, Takacs, Peter, Chatterjee, Archana, Sperling, Rhoda S, Chakhtoura, Nahida, Blatter, Mark M, Lalezari, Jacob, David, Marie-Pierre, Lin, Lan, Struyf, Frank, Dubin, Gary
Published 2014

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis

by Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max
Published 2014

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis

by Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max
Published 2014

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

by Berkowitz, Elchonon M., Moyle, Graeme, Stellbrink, Hans-Jürgen, Schürmann, Dirk, Kegg, Stephen, Stoll, Matthias, El Idrissi, Mohamed, Oostvogels, Lidia, Heineman, Thomas C., Brockmeyer, Norbert, deJesus, Edwin, Esser, Stefan, Hawkins, Trevor, Lalezari, Jacob, Orkin, Chloe, Schneider, Stefan
Published 2015

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

by Wei, Datsen George, Chiang, Vicki, Fyne, Elizabeth, Balakrishnan, Mini, Barnes, Tiffany, Graupe, Michael, Hesselgesser, Joseph, Irrinki, Alivelu, Murry, Jeffrey P., Stepan, George, Stray, Kirsten M., Tsai, Angela, Yu, Helen, Spindler, Jonathan, Kearney, Mary, Spina, Celsa A., McMahon, Deborah, Lalezari, Jacob, Sloan, Derek, Mellors, John, Geleziunas, Romas, Cihlar, Tomas
Published 2014

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

by Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A
Published 2015

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

by Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor
Published 2013